Core Viewpoint - Alpha Teknova, Inc. has announced a definitive agreement for a private placement of 12,385,883 shares of common stock at a price of 15.4 million before expenses [1][7]. Company Overview - Teknova is a leading producer of critical reagents for the life sciences industry, focusing on the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics [1][4]. - The company has been innovating since 1996 and offers customizable solutions for various stages of the workflow, supporting sectors such as cell and gene therapy, molecular diagnostics, and synthetic biology [4]. Financial Details - The private placement is expected to close on or about July 12, 2024, subject to customary closing conditions [7]. - The gross proceeds from the private placement are anticipated to be approximately $15.4 million, which will be used for general corporate purposes [7]. Regulatory Compliance - The securities in the private placement are not registered under the Securities Act and may not be reoffered or resold in the U.S. without an effective registration statement or applicable exemption [3][8]. - Teknova has agreed to file an initial registration statement with the SEC covering the resale of the securities within 45 days of the definitive agreement [8].
Teknova Announces $15.4 Million Private Placement